Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer. [electronic resource]
Producer: 20090129Description: 1293-300 p. digitalISSN:- 1556-1380
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Celecoxib
- Cyclooxygenase 2 Inhibitors -- administration & dosage
- Docetaxel
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Staging
- Prognosis
- Pyrazoles -- administration & dosage
- Sulfonamides -- administration & dosage
- Survival Rate
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.